After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association
This step prevents introducing bacteria or contaminants into either vial
Even mild thyroid underperformance slows metabolic rate and reduces cellular energy
exenatide and dulaglutide show no benefit Reductions in depressive symptoms with semaglutide appear independent of weight loss, suggesting a direct neurobiological mechanism Semaglutide is associated with reduced suicidal ideation in large real-world cohorts Addiction is the perhaps the most exciting signal in the literature: Confirmed reductions across alcohol, nicotine, opioid, and cocaine use disorders Alcohol: reductions in alcohol consumption, craving, relapse rates, alcohol-related diagnoses, and alcohol-related hospitalization, exceeding naltrexone Opioids: 40 to 68% lower overdose risk across multiple large cohorts Nicotine: 12-30% decrease in tobacco use disorder diagnoses, and 40-70% reduction in smoking cessation medication Eating disorders: Binge eating disorder: reduces binge episodes, cravings, and symptom scores Bulimia nervosa: reduces binge-purge frequency and episodes Restrictive eating disorders: numerous case reports document reactivation of past anorexia The psychiatric risks: In patients with a low dopamine, GLP-1s may worsen depression or trigger suicidal ideation, the opposite of the benefit seen in most patients Case reports of anhedonia, emotional flatness, and personality change Psychiatric benefits are most clearly established in patients with pre-existing depression, anxiety, or diabetes
These reactions generally indicate that the protocol is working, and I closely monitor patients to adjust treatment as needed
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
